The Best ASX Healthcare Stocks
to buy Now In
May 2025

Check out our Industry Experts’ report and
analysis on the Best Healthcare Stocks right now on the ASX

The Best ASX Healthcare Stocks to buy Now In May 2025

Check out our Industry Experts’ report and analysis on the Best Healthcare Stocks right now on the ASX

Pathway to Investment in ASX Healthcare Stocks

money-bag-1

Before investing in these ASX healthcare stocks, or stocks in any other sector for that matter, investors should examine a company's earnings, revenue, and its market cap, capitalisation, cap and its market capitalisation first. Companies like Pro Medicus and CSL (among others companies) have managed to maintain steady earnings. Analysing the company's share price and valuation is crucial.

Group 525

A company's business success in other industries as the healthcare sector is often tied to its ability to develop and sell innovative healthcare products, treatments, and services that meet market demand. Clinical trials for new treatments are a good indicator of ASX healthcare stocks' future profit potential - if of course the clinical trials themselves are successful and regulators approve.                

best-dividend-icon-3

Investors should assess their risk tolerance before investing in healthcare companies and stocks. Although healthcare companies and stocks are generally considered defensive, investing the sector can still be affected by factors such as regulatory changes and advancements in technology. An individual's investment decision should be based on their financial goals, risk tolerance, and timeline.

Get the Latest Stock Market Insights for Free with
Stocks Down Under & Pitt Street Research

Join our newsletter and receive exclusive insights, market trends, investment tips, and updates delivered directly to your inbox. Don't miss out – subscribe today and make informed investment decisions.

A Deep Dive into Top ASX Healthcare Stocks

The healthcare sector industry in Australia has been a significant growth area for companies in the Australian Securities Exchange (ASX) for years. Despite the volatility index of health care sector in the world of markets, the ASX healthcare sector index has shown defensive qualities due to consistent market demand for healthcare services, supplies pathology services and products.

The sector is home to a handful of established companies like CSL (ASX:CSL) that are world-renowned names and make multi billion dollar profits as well as a significant difference to the lives of many around the world. Then there are several dozen companies that are developing drugs of medical devices that they hope can become the next big blockbuster product, ranging from companies at the final clinical trial stage to companies that haven't even commenced clinical work yet.

ASX investors have made spectacular returns on certain companies that have realised this dream, such as Telix (ASX:TLX) and Neuren (ASX:NEU) in recent years. At the same time, it is a long hard slog to get a drug or device to market, and the dream can fail at multiple hurdles along the way, such as through clinical trials failing. And even established companies can endure challenges such as flat demand for their products, major cost inflation and competition. Investors in healthcare stocks have been concerned about the latter two issues with several big name stocks in the past year - specifically the weight loss drug Ozempic.

Ultimately, the ASX Healthcare sector presents several opportunities for investors to make money and to make it through companies making a major difference to the lives of the population.

3 Best ASX Healthcare Stocks to Buy Now in 2025

CSL (ASX: CSL)

CSL is one of the most prominent companies in the Australian healthcare sector and a global leader in biopharmaceuticals. Founded in 1916, the company has grown into a powerhouse in immunology, haematology, and vaccines...

Dimerix (ASX: DXB)

Dimerix is an emerging Australian biotechnology company focused on addressing unmet medical needs, primarily in the areas of kidney diseases and respiratory conditions. The company’s leading drug candidate, DMX-200, is being developed for diabetic kidney...

Cochlear (ASX: COH)

Cochlear is a globally recognised leader in implantable hearing solutions, offering advanced cochlear implants that have transformed the lives of individuals with severe hearing loss. The company’s products, which include the Nucleus cochlear implant system...

3 Best ASX Healthcare Stocks to Buy Now in 2025

CSL (ASX: CSL)

CSL is one of the most prominent companies in the Australian healthcare sector and a global leader in biopharmaceuticals. Founded in 1916, the company has grown into a powerhouse in immunology, haematology, and vaccines. CSL’s core offerings include immunoglobulins, clotting factors, and vaccines, which are essential for treating rare and serious conditions.

CSL’s flagship product, Hizentra, is a leading immunoglobulin therapy used by patients with immune deficiencies. Over the years, the company has strategically acquired and developed high-value assets, expanding its global reach with operations in over 35 countries. CSL’s ongoing commitment to research and development ensures a strong pipeline of new therapies that promise to address growing healthcare needs.

With its strong financial performance, driven by consistent revenue growth and significant investments in R&D, CSL is often considered a safe and reliable investment. Moreover, the company has a solid history of paying dividends, making it attractive for income-focused investors. CSL’s resilience and ability to innovate within the biopharmaceutical industry have made it a top pick for investors seeking exposure to the healthcare sector.

Dimerix (ASX: DXB)

Dimerix is an emerging Australian biotechnology company focused on addressing unmet medical needs, primarily in the areas of kidney diseases and respiratory conditions. The company’s leading drug candidate, DMX-200, is being developed for diabetic kidney disease, a condition that affects millions globally.

Dimerix is also exploring the use of its proprietary technology for other therapeutic applications, including fibrosis and asthma. While still in the early stages of development, Dimerix’s innovative approach to drug discovery has garnered significant attention from both the medical community and investors. The company is actively advancing through clinical trials, and successful outcomes could position Dimerix as a major player in the biotech space.

For investors, Dimerix offers a high-risk, high-reward proposition, with substantial upside potential should its treatments achieve regulatory approval. The stock is well-suited for investors with a higher risk tolerance who are looking for opportunities in the rapidly advancing biotech industry. However, the potential volatility and unpredictability of clinical trial results are factors to consider before making an investment decision. With promising drug candidates and a growing research pipeline, Dimerix is one to watch in the biotech space.

Cochlear (ASX: COH)

Cochlear is a globally recognised leader in implantable hearing solutions, offering advanced cochlear implants that have transformed the lives of individuals with severe hearing loss. The company’s products, which include the Nucleus cochlear implant system, provide a life-changing alternative to traditional hearing aids for people with profound hearing loss.

Since its founding in 1981, Cochlear has become the dominant player in the market for implantable hearing solutions, with a significant global market share and a broad customer base. The company operates in more than 100 countries and has implanted over 600,000 devices worldwide. Cochlear continues to innovate, developing new technologies and enhancing the effectiveness of its implants.

The company’s robust revenue model is supported not only by the sale of implants but also by ongoing maintenance services and accessories. Cochlear’s long-standing commitment to research and development ensures its competitive edge in the market. For investors, the company offers stability, with a proven track record of strong earnings growth and a commitment to shareholder value through dividends and share buybacks. Cochlear is well-positioned to benefit from the increasing demand for hearing solutions globally, particularly as the ageing population grows. For those looking for a dependable and innovative healthcare investment, Cochlear represents an attractive opportunity.

FAQs on Investing in Healthcare Stocks

The iShares Global Healthcare ETF provides exposure to a range of global healthcare stocks, including those listed on ASX. It aims to track the performance of the S&P Global 1200 Healthcare Sector Index.

Our Analysis on ASX Healthcare Stocks

ASX:MSB

Mesoblast (ASX:MSB): Will it thrive or just survive in 2024?

November 28, 2023

Mesoblast’s (ASX:MSB) struggle with regenerative medicine in 2023 involved kеy financial movеs as wеll as opеrational rеstructurings. Thе entity which…

Is Ramsay Hеalth Carе a Hidden Gem or a Falling Star?

November 25, 2023

Ramsay Hеalth Carе Ltd (ASX: RHC) saw an 11.6% rеvеnuе surgе to $15.3 billion in FY23, Ramsay is going through…

Atriva Therapeutics

Atriva Therapeutics – a new take on influenza antivirals

November 20, 2023

In September 2023 a privately held German drug development company called Atriva Therapeutics announced that it was going to go…

Intеgral Diagnostics

Intеgral Diagnostics experienced a sudden 25% sharе pricе dip last week: What should Investors make of it?

November 10, 2023

Intеgral Diagnostics (ASX: IDX) has recently еxpеriеncеd a significant dip in its sharе pricе, dropping by over 25% on last…

ozempic

Ozempic: Here’s why 2023’s star obesity treatment is causing headaches for CSL and several other biotech stocks

October 19, 2023

Ozempic is one of the few things giving CSL (ASX:CSL) shareholders sleepless nights right now. And you could argue this…

fda approval

FDA approval: Here’s how ASX biotechs and medtechs obtain it

October 9, 2023

Last week one of our favourite companies Cyclopharm (ASX:CYC) obtained FDA approval, a goal it had been striving for years…